Recruiting

Ovarian & Pelvic Vein Embolization

Sponsor:

Weill Medical College of Cornell University

Code:

NCT06168058

Conditions

Chronic Pelvic Pain Syndrome

Pelvic Pain

Pelvic Varices

Pelvic Congestive Syndrome

Pelvic Pain Syndrome

Eligibility Criteria

Sex: Female

Age: 18 - 70+

Healthy Volunteers: Accepted

Interventions

Transcatheter Venography

Bilateral ovarian vein embolization

Study Details

Brief summary:

The purpose of this study is to see if a randomized controlled trial of ovarian vein and pelvic vein embolization versus venography alone could determine outcomes for women with chronic pelvic pain and pelvic varicose veins.

The data gathered will assist in addressing changes in quality of life in patients who have ovarian/pelvic vein embolization versus no embolization.

Conditions

Chronic Pelvic Pain Syndrome

Pelvic Pain

Pelvic Varices

Pelvic Congestive Syndrome

Pelvic Pain Syndrome

Study ID

NCT06168058

Start date

Oct 29, 2025

Status verified date

Aug, 2026

Completion date

Jun, 2027

Anticipated

Primary completion date

Jun, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 18 - 70+

Healthy Volunteers: Accepted

Inclusion Criteria:

1. Presence of venous origin chronic pelvic pain for greater than 6 months (VAS ≥7 as determined by 4 consecutive weeks of baseline self-assessments) despite non-vascular therapy as delineated by the following criteria:

  • Pain exacerbated by walking, standing or lifting
  • Symptoms are at least partially alleviated by lying down
  • Prolonged post-coital ache
  • Absence of non-venous origin CPP as determined by Gynecology examination
2. Symptoms-Varices-Pathophysiology Classification18 including of one of the following:

•S2V2PBGV,R,NT, S2V2PRGV,R,NT , S2V2PLGV,R,NT, with or without S2V2 PBIIV,R,NT, S2V2 PLIIV,R,NT, S2V2 PRIIV,R,NT
3. CT, TAUS and diagnostic venography (if needed) imaging review for pelvic venous imaging factors

  • Left or right ovarian vein diameter greater than or equal to 6 mm as documented by TAUS or CT
  • Presence of intrabdominal/pelvic varices as documented by TAUS or CT (≥1 veins, >5 mm diameter)
  • Presence of venous reflux in ovarian and/or internal iliac veins without evidence of hemodynamically significant stenosis

Exclusion Criteria:

  • Female <18 years of age
  • Pregnancy (positive pregnancy test)
  • Female subject who plans to become pregnant during study period
  • Female subject who is actively breastfeeding
  • Patient who is post-menopausal or anovulatory with hormone suppression
  • History of prior hysterectomy
  • Prior ovarian vein embolization or ovarian vein ligation
  • Inability to tolerate endovascular procedure due to acute illness or general health
  • Planned simultaneous treatment with nerve blocks during the duration of the study
  • Laparoscopy or planned surgical intervention during the duration of the study
  • Known allergy to sclerosant, coil, stent or catheter components including nickel allergy
  • Any iliac vein stenosis determined identified by the investigator on pelvic DUS, CT venogram, and/or Catheter Venography and deemed significant for exclusion by study patient review committee.
  • Any renal vein stenosis with resultant renal hilar varices/collaterals and lumbar collaterals identified by the investigator on pelvic DUS, CT venogram, and/or Diagnostic Venography and deemed significant for exclusion by study patient review committee.
  • Presence of isolated extra-pelvic vulvar and/or lower extremity varices without intrabdominal pelvic varices. Primary S3 categorization study exclusion.
  • Serious medical conditions that might preclude full participation in the study to the desired endpoint (e.g., uncontrolled diabetes, malignancy, COPD, MI, CHF, etc.)
  • Severe allergy to iodinated or gadolinium-based contrast refractory to steroid premedication
  • Severe renal impairment (on chronic dialysis or estimated GFR <30 mL/min)
  • Hemoglobin <8.0 g/dL, uncorrectable INR >3.0 or platelet count <75,000/microliter
  • Inability to provide informed consent or to comply with study assessments
  • Post thrombotic IVC, iliac or ovarian vein changes

Study Design

Enrollment

40 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

sham comparator: Transcatheter Venography

experimental: Bilateral Ovarian Vein Embolization

Transcatheter Venography plus Bilateral Ovarian Vein Embolization.

Interventions

Transcatheter Venography

Venographic assessment of ovarian veins and internal iliac veins

Bilateral ovarian vein embolization

Intervention will include sclerosis of pelvic varices and coil embolization of the bilateral ovarian veins.

Primary outcome measure

  • Change in Visual Analog Scale (VAS) for pelvic pain [ Time Frame: Weekly for 4 weeks prior to Day 1 and at 30, 90 and 180 day follow up ]

Central Contacts and Locations

Central contacts

Locations

Northwell Health Physician Partners Vascular Surgery

Recruiting

New Hyde Park, New York, United States, 11042

Weill Cornell Medicine

Recruiting

New York, New York, United States, 10024

Principal Investigator:

Neil K Khilnani, MD

UNC School of Medicine

Recruiting

Chapel Hill, North Carolina, United States, 27599

Principal Investigator:

Gloria Salazar, MD

More Information

Sponsor

Weill Medical College of Cornell University

Last update posted

Aug 20, 2026

Last verified

Aug, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Weill Medical College of Cornell University on 2026-08-20.